BridgeMD
New treatment option for Amyotrophic Lateral Sclerosis
Official title A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)
ClinicalTrials.gov ID: NCT07571200
What this study is testing
What is LY4256984?
LY4256984 is an investigational medicine, being studied as a potential treatment for amyotrophic lateral sclerosis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Study OLMP is a master protocol that will support a collection of individual sub studies that share key design components. Participants from the originator study OWAA (NCT07100119) will be assigned to the appropriate study treatment group: Sporadic Amyotrophic Lateral Sclerosis OL01 (NCT07571174).
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Participants must meet eligibility criteria below. Additional criteria are specified in the substudy to which the participant will enroll.
- Have completed an eligible parent study, as determined by the investigator. Eligible parent studies will be defined by the sponsor but will be...
- Note 1: To be considered a "completer" of a parent study, the participant must finish the main treatment period/phase of the parent study as well as...
- Note 2: Visits missed in a parent study will have no impact on the completer status of a potential participant.
You likely can't join if
- During the parent study, the participant permanently or temporarily discontinued the investigational medicinal product (IMP), such that restarting...
- During the parent study, the participant experienced extreme ALS disease progression (for example, permanent mechanical ventilation) that poses an...
- During the parent study, the participant developed an unresolved SAE or a medical illness (other than ALS) that, in the opinion of the investigator...
The study team makes the final eligibility decision.
Where it's taking place
- Leuven, Belgium
- London, Canada
- Montreal, Canada
- Toronto, Canada
- Lübeck, Germany
- Rostock, Germany
- Ulm, Germany
- Utrecht, Netherlands
- L'Hospitalet de Llobregat, Spain
- Valencia, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Leuven, Belgium; London, Canada; Montreal, Canada; Toronto, Canada; Lübeck, Germany; Rostock, Germany and 4 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.